If you will be receiving Tisagenlecleucel as standard-of-care and if you meet the following qualifications below, you may receive Tisagenlecleucel as an out-of-specifications product through the Managed Access Program (MAP).This is a special access program for patients with ALL or large B cell lymphoma who:
T-cells (a type of white blood cell) have been removed from your blood and modified in order to target the leukemia and or lymphoma and then will be returned back to you. The T-cells will be changed in a way that can allow them to identify and possibly kill your tumor cells which are B-cells. The modification of the T-cells is done by a process called gene transfer which results in genetic modification to the T-cells taken from your body. The modified T-cells are called CTL019 cells or Tisagenlecleucel.
Detailed eligibility will be reviewed when you contact the study team.